In the face of biotech after the wave of people blessed and so on a group of traditional pharmaceutical companies how to "live" reverse...

In today's biopharmaceutical industry, survival rules are changing dramatically, and traditional drug companies must make a choice in the face of the surging local emerging biotech.
It is clear that, whether through mergers and acquisitions, independent research and development, project introduction, cooperation and so on, only traditional enterprises that are good at learning from successful experiences and taking the lead in completing the layout will win market opportunities and benefit from transformation and upgrading.
, the crisis awareness of traditional pharmaceutical companies has been in the fore since 2015.
time, many traditional pharmaceutical companies have begun the layout of innovation transformation, and now their innovative research and development is ushering in the second and third phase of clinical and even approved key nodes for listing.
with the domestic innovation drug review and approval and medical insurance payment reform, the normalization of national collection and development, the transformation and innovation of traditional pharmaceutical enterprises is still in time? "Innovation transformation is never too late.
2020, as a leader in innovation transformation, Xinlitai transferred two generic drugs for 84 million yuan, in order to better focus on innovative research and development.
fact, this is not the first time Xinlitai "bear the pain of cutting love."
in order to carry out innovative research and development around the core areas of cardiovascular, orthopaedic, hypoglycemia and other core areas, Xinlitai has terminated a number of clinical phase of generic drug projects.
in addition to the determination, whether the smooth transformation of enterprises is also affected by the product line layout.
And biotech company is different, the traditional pharmaceutical companies are more combined with the characteristics of their existing products for layout, whether it is independent research and development innovation or project introduction, the transformation of traditional pharmaceutical companies, should rely on their own advantages and advantages of the track, blind cross-field research and development, will also appear more than half the effect.
Innovating transformation is becoming every traditional pharmaceutical companies standing at the crossroads of bend oversteps or "death" can not avoid the topic, when there are Hengrui Pharma, Fosun Pharma, China Biopharmaceuticals and so on a number of prophetic traditional pharmaceutical companies to become industry pioneers and models, to people-friendly medicine, Luoxin pharmaceutical industry, Osaikang pharmaceutical industry, Yifan medicine as the representative of more traditional pharmaceutical companies, transformation is still on the road ... 01 People's fu medicine: "nuclear" road to the long use of "ten years a sword" to describe human blessing medicine is not exaggerated.
, which took 10 years to develop, was officially approved for listing in July last year, breaking the nearly 30-year non-innovative drug market in the field of sedative drugs widely used clinically at home and abroad.
" marks a milestone leap in our research and development capabilities from keeping pace and leading the way.
, chairman of the People's Fu Pharmaceutical Group, has said publicly.
in the nearly 30 years since the establishment of Human Fu Pharmaceuticals, the business has involved real estate, finance, condoms, blood products, narcotic drugs and other industries, foreign investment includes environmental protection, real estate, finance, education and other industries.
However, since 2017, People's Fu Pharmaceuticals has also embarked on the tide of return to the main industry, for the first time put forward a "nuclear return plan", "in further strengthen and expand the core business at the same time, actively and firmly divest non-core business and assets, choose the opportunity to withdraw from the pharmaceutical industry, pharmaceutical business and medical services section of the competitive advantage is not obvious Or weak synergies in the sub-sectors, and constantly optimize the company's business structure and asset structure", by 2019 confirmed as "a comprehensive combing of the product line, focusing resources on the development of narcotic drugs, other nervous system drugs, health drugs, Uyghur ethnic drugs, skin drugs, respiratory drugs and other core areas."
People's Fu Pharmaceuticals to promote the nuclear focus strategy, on the one hand, adhere to the focus of resources to develop established professional sub-areas to achieve business focus, the other side has been divesting non-core pharmaceutical assets, and continuously optimize the business, capital structure.
2019, People's Fu Pharmaceuticals has divested regional pharmaceutical commercial assets, non-core pharmaceutical enterprises, medical services projects, with a cumulative return of more than 4 billion yuan.
To this person Fu pharmaceutical said that the increase and divestiture, are the group's core assets to further strengthen, is conducive to the optimization and focus of the business structure, is conducive to the company to further optimize the asset-liability structure, focus on the development of competitive advantage in the sub-areas.
Yichang People's Fu is considered to be the core asset of Manfu Pharmaceuticals, which has maintained a relatively steady growth rate in recent years.
2018-2019, net profit was 802 million yuan and 1.105 billion yuan, respectively, up 28.47 percent and 37.37 percent year-on-year, respectively, and its contribution to the net profit of listed companies increased to 77 percent (regardless of goodwill impairment) and 82 percent, according to relevant data.
"nuclear" strategy makes people bless medicine in the domestic anesthetic analgesia, fertility regulation drugs, Uyghur drugs and other sub-sectors to establish a leading position.
At present, More than 200 products are being studied by People's Fu Pharmaceuticals, more than 20 are being studied for a class of new drugs, 24 projects are listed as major new drug creation projects in the country, and 2 projects have been established by the National Supreme Technical Research and Development Plan (863 Plan).
analysis points out that the narcotics business of Humane Pharma benefits from policy-based industry barriers and industry growth space, and the future is worth looking forward to.
02 Rohingya Pharmaceuticals: The first shot of innovation transformation January 3, 2021, Luoxin Pharmaceuticals announced that its research and development of a class 1 digestive innovation drug - potassium ion competitive acid blocker (P-CAB) LXI-15028 officially received the CDE listing application, which is the second P-CAB products officially reported.
the drug was authorized by Rohingya Pharmaceuticals in October 2015 to introduce CJ HealthCare, which is responsible for the development, production and commercialization of the drug in Chinese mainland.
, three potassium ion competitive acid blockers have been approved for market worldwide: Revaprazan, Vonoprazan and Tegoprazan.
2019 sales of medicines for the treatment of stomach acid secretion-related diseases in public medical institutions in China amounted to 42.379 billion yuan, according to the Company's data.
On January 14, Rohingya Pharmaceuticals announced that it had submitted to the State Drug Administration an application for the listing of a new class of pharmaceutical chemicals for gora tablets, targeting H-K plus ATPase, with a certificate of 12-finger intestinal ulcers, esophoitis, gastroesoesis reflow.
these advances are significant for Rosin Pharmaceuticals.
as a baptist in the capital markets, Rosin Pharmaceuticals will start again in May 2020.
it is understood that Luo Xin Pharmaceutical Co., Ltd. was restructured and restructured by Luo Xin Pharmaceutical Co., Ltd. in 2001 and landed on the HONG Kong Stock Exchange GEM in 2005, with a cumulative dividend of more than HK$1 billion in the ten years from 2006 to 2015.
, Mr Loh Hin Pharmaceuticals, submitted three applications to the HKEx for a transfer board, all of which were rejected.
in June 2017, Rohingya Pharmaceuticals voluntarily privatized and de-marketed. in terms of
share price, in December 2005, The issue price of Luo Xin Pharmaceuticals on the GEM of the Hong Kong Stock Exchange was HK$0.26 per share, and in June 2017, the privatization offer price of Luo xin Pharmaceuticals was HK$17 per share, a premium of approximately 31.78 per cent over the closing price of HK$12.9 per share in the last trading day.
On May 12, 2020, Shandong Luoxin Pharmaceutical Group Co., Ltd. successfully closed its shares in Dongyin by shell, and Dongyin Shares Changed Securities was referred to as "Rohingya Pharmaceuticals", marking the official entry of Luoxin Pharmaceuticals into the A-share capital market.
in terms of performance, according to the Earnings Compensation Agreement signed by Dongyin Shares and Rohingya Pharmaceuticals on December 27, 2019, Rohingya Pharmaceuticals' committed parties have committed to Net profit achieved in 2020, 2020 and 2021 was not less than 550 million yuan, 650 million yuan and 750 million yuan, respectively.
Pharmaceuticals is a leader in the fields of digestive and respiratory drugs, and has a complete industrial chain from API to preparation.
2019, Luoxin Pharmaceuticals invested a total of 486 million yuan in research and development, according to its annual report.
through the adoption of independent research and development and cooperative research and development combined model, is actively layout innovative research and development upgrade, the current innovative drug pipeline has more than 10 varieties, not only focus on digestion, respiratory, anti-tumor and other areas of clinical urgent needs of drugs.
03 Osaikang Pharmaceuticals: Innovation and high-end first imitation multi-point flowering PPI injection leader, is now emerging in the field of oncology.
was founded in 2003 Osaikang Pharmaceuticals, focusing on china's pharmaceutical market segment, product dosage forms include freeze-dried powder needle preparations, solid oral preparations, in the domestic anti-peptic ulcer drug proton pump inhibitor injection (PPI injection) product segment market share first, PPIs product group covers six domestic listed PPI injections, are the first or first market share.
as a leading domestic PPI injection enterprises, Osaikang is expected to occupy an advantage in injection collection.
in the research pipeline a number of heavy-duty "innovative drugs and high-end first imitation" series of varieties differentiated layout, is expected to rely on "independent research and development and variety introduction" and other ways to successfully transform.
in the study of injections with right-handed reberazole sodium, injection with L-vitolazole sodium, injection with right-handed lanso laazole, right-handed lanso laazole slow release capsules and other varieties, help to continue to consolidate and develop the leading position in the field of injection proton pump inhibitors, to achieve its sustainable development.
in recent years, Osaikang's anti-tumor sector has gradually increased its share of the company's revenue, and its early cancer innovation drugs have emerged.
July 9, 2020, Osaikang anti-tumor biopharmaceity drug ASKB589 has been approved for clinical trials of the drug, and the first phase of clinical patients is about to be launched.
As its own research and development, with independent intellectual property rights of the large molecules of a class of innovative drugs, ASKB589 is a domestic target Claudin 18.2 antibody drugs, intended for use in the stomach and gastroesophageal binding adenocarcinoma, pancreatic cancer and other adaptations.
the number of targeted treatment drugs approved for stomach cancer worldwide is relatively small, and Claudin18.2 targeted drugs have significant market advantages in the future and are expected to become an effective target treatment variety for stomach cancer.
domestic and foreign products have not been approved for listing, there is a great clinical demand, market potential.
addition, a new class 1 drug approved for clinical trials in 2017, ASK120067, has also made progress.
This product is a third generation EGFR inhibitor, targeted at T790M, used to treat non-small cell lung cancer, in 2019 won the National 13th Five-Year Plan "major new drug creation" science and technology major special projects, and obtained CDE recognition, after the completion of clinical II.
with the gradual easing of the epidemic nationwide, clinical research has returned to normal, is expected to complete phase II clinical entry by the end of the year, in 2021 to apply for listing of CDE.
2019, Osaikang achieved operating income of RMB4,519 million, up 14.93% YoY, total profit of RMB910 million, up 20.60% YoY, and net profit of RMB793 million, up 18.41% YoY, maintaining a steady upward trend.
.4 billion fan medicine: 2021 seeking the listing of 10 million organisms in July 2020, Yifan pharmaceutical ushered in its transformation of innovative pharmaceutical field since the high-gloss moment.
On the afternoon of July 7, 2020, Yifan Pharmaceuticals held an on-site description of the results of the International Phase III clinical trial of the innovative biopharmaceutical Begsting (F-627 long-acting recombinant human granulocyte collection stimulation factor-Fc fusion protein).
meeting, Yifan Pharmaceuticals announced that the F-627 and neulasta produced by the original AAE, have completed Phase III clinical trials, are expected to complete the construction of the preparation plant in 2020, domestic production in 2021, and overseas production by the end of 2020, F-627 after the listing of domestic and foreign sales of at least 300 million to 400 million U.S. dollars.
F-627 original drug Neulasta's successful commercial operations have created a global market of $7 billion, but Yifan Pharmaceuticals remains confident and says that in the U.S. and Europe, the future pricing and market share of the F-627 will not be lower than that of any biosypolybic drug.
and Efan Pharmaceuticals also has a luxurious management team for EVIVE, including former FDA officials, former Sanofi Global Medical Vice President, and cfOs with experienced capital operations, all of which have a successful track record working for multinational pharmaceutical/biopharmaceutical companies and regulators.
F-652, another new drug called Yifan Pharmaceuticals, is called "Gold Oil".
F-652 (recombinant human interlebin 22-Fc fusion protein) is intended for the treatment of acute tissue damage and inflammatory diseases, including the treatment of graft anti-host disease (GVHD), acute pancreatitis, acute alcoholic hepatitis, pneumonia/COVID-19, drug damage and heart transplantation.
currently, F-652 has passed FDA Phase 2a clinical trials in both Graft Anti-Host Disease (GVHD) and Acute Alcoholic Hepatitis Adaptation, and is eligible for GVHD orphan drugs.
of the transformation of 100 million fan medicine is largely supported by other mature businesses.
understood that Yifan Pharmaceuticals was established in 2000, in 2014 shell Xinfu Pharmaceuticals landed A shares.
Its main business is divided into three parts, one is the subsidiary Hangzhou Xinfu Pharmaceuticals vitamin B5 raw materials and polymer materials;
It is worth mentioning that Yifan Pharmaceutical is one of only six vitamin B5 (calcium pan-calcium panate) producers in the world, with a production capacity of about 8000 tons to 12,000 tons, accounting for about 40% of the total global production capacity.
2016 Yifan Pharmaceuticals to accelerate the transformation of innovative drugs as its focus area of development.
in April 2016, Yifan Pharmaceuticals acquired a 62.04% stake in DHY (Evive) for approximately RMB 1 billion, and Kenon Lung owns two new drug development platforms, DiKineTM Dual Molecules and ITabTM Immunoantibodies.
since then, Yifan Pharmaceuticals has developed F-627, F-652 and other large-molecule bio-innovative drugs based on the EVIVE technology platform, and has transformed into an international large-molecule innovation drug platform-based enterprise strategy.
meeting on July 7, 2020, Yifan Pharmaceuticals announced that Jiannenglong will officially be renamed Evive BIOTEC